NOVARTIS AG
Related Filers (48)
- Novartis Bioventures Ltd (85)
- IDENIX PHARMACEUTICALS INC (34)
- NOVARTIS PHARMA AG (33)
- Novartis Capital CORP (25)
- ALCON INC (20)
- AILERON THERAPEUTICS INC (16)
- Altimmune, Inc. (14)
- Ra Pharmaceuticals, Inc. (12)
- Novartis Securities Investment Ltd. (12)
- ALNYLAM PHARMACEUTICALS, INC. (11)
- Aerpio Pharmaceuticals, Inc. (10)
- Novartis Institutes for BioMedical Research, Inc. (10)
- GENOPTIX INC (8)
- Tokai Pharmaceuticals Inc (8)
- Advanced Accelerator Applications S.A. (8)
- Galera Therapeutics, Inc. (7)
- EON LABS INC (6)
- MOMENTA PHARMACEUTICALS INC (6)
- Intellia Therapeutics, Inc. (6)
- Aeglea BioTherapeutics, Inc. (6)
- AveXis, Inc. (6)
- ENDOCYTE INC (6)
- MEDICINES CO /DE (6)
- Marina Biotech, Inc. (5)
- CHINOOK THERAPEUTICS, INC. (4)
- JPMorgan Chase Bank, N.A. - ADR Depositary (3)
- BlackRock Inc. (3)
- ORGANOGENESIS INC (2)
- NOVARTIS CORP (2)
- Novartis Finance Inc. (2)
- ARROWHEAD PHARMACEUTICALS, INC. (2)
- PROTEOSTASIS THERAPEUTICS, INC. (2)
- XOMA Corp (2)
- Homology Medicines, Inc. (2)
- Surface Oncology, Inc. (2)
- BICYCLE THERAPEUTICS plc (2)
- Akouos, Inc. (2)
- Poseida Therapeutics, Inc. (2)
- MorphoSys AG (2)
- ISIS PHARMACEUTICALS INC (1)
- CELL GENESYS INC (1)
- CHIRON CORP (1)
- CELL THERAPEUTICS INC (1)
- resTORbio, Inc. (1)
- Forma Therapeutics Holdings, Inc., (1)
- Cellular Biomedicine Group, Inc. (1)
- PRECISION BIOSCIENCES INC (1)
- Kowalski Robert William (1)
- Show More ...
Other (1011)
20-F
Wednesday, 1/31/2024
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
IRANNOTICE
Wednesday, 1/31/2024
Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
6-K
Wednesday, 1/31/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 1/31/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 1/8/2024
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 12/11/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 12/6/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 11/28/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 10/30/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 10/24/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 10/4/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 10/2/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
144
Tuesday, 9/19/2023
Filing for proposed sale of securities under Rule 144
6-K
Tuesday, 9/5/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 8/21/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 8/9/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 7/18/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 7/10/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 6/12/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
SD
Wednesday, 5/31/2023
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
20-F/A
Monday, 5/15/2023
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
CORRESP
Tuesday, 5/9/2023
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
6-K
Tuesday, 4/25/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 3/27/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
20-F
Wednesday, 2/1/2023
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
6-K
Wednesday, 2/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 2/1/2023
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
IRANNOTICE
Wednesday, 2/1/2023
Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
F-6 POS
Friday, 12/16/2022
Post-effective amendment to a F-6EF registration
6-K
Monday, 12/5/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 10/25/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 10/24/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 9/21/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 8/25/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 7/19/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 6/21/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
SD
Tuesday, 5/31/2022
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
6-K
Tuesday, 4/26/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
20-F/A
Tuesday, 4/26/2022
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
6-K
Monday, 4/4/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 3/24/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
IRANNOTICE
Wednesday, 2/2/2022
Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
20-F
Wednesday, 2/2/2022
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
6-K
Wednesday, 2/2/2022
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 12/22/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 12/20/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 12/17/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 11/4/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 10/26/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 10/25/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 8/3/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 7/21/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 6/28/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
SD
Tuesday, 6/1/2021
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
6-K
Tuesday, 4/27/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 3/23/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 3/22/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 3/9/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 3/5/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 2/16/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 1/29/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
IRANNOTICE
Tuesday, 1/26/2021
Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
20-F
Tuesday, 1/26/2021
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
6-K
Tuesday, 1/26/2021
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
CORRESP
Tuesday, 1/19/2021
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
6-K
Monday, 12/21/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 11/24/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 10/27/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 10/16/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 9/23/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 9/1/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 8/20/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 8/17/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 7/21/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 7/2/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 6/25/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 6/17/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
SD
Monday, 6/1/2020
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
6-K
Tuesday, 5/12/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 4/28/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 4/2/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 3/27/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 3/27/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 3/19/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 3/2/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 2/28/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
POSASR
Friday, 2/14/2020
Post-effective Amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR
6-K
Friday, 1/31/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
F-3ASR
Thursday, 1/30/2020
Automatic shelf registration statement of securities of well-known seasoned issuers
IRANNOTICE
Wednesday, 1/29/2020
Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
6-K
Wednesday, 1/29/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
20-F
Wednesday, 1/29/2020
Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)
6-K
Monday, 1/6/2020
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 12/16/2019
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Thursday, 12/5/2019
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Monday, 11/25/2019
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 11/15/2019
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Friday, 11/1/2019
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Wednesday, 10/30/2019
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
6-K
Tuesday, 10/22/2019
Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Ownership (184)
SC 13G/A
Friday, 2/2/2024
BlackRock Inc.: Major Shareholders
SC 13G/A
Wednesday, 2/1/2023
BlackRock Inc.: Major Shareholders
3
Monday, 6/27/2022
PRECISION BIOSCIENCES INC: Initial statement of beneficial ownership of securities
SC 13G
Friday, 2/4/2022
BlackRock Inc.: Major Shareholders
SC 13G/A
Wednesday, 8/19/2020
XOMA Corp: Major Shareholders
3
Friday, 8/14/2020
Cellular Biomedicine Group, Inc.: Initial statement of beneficial ownership of securities
4
Thursday, 7/16/2020
Poseida Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
3
Monday, 7/13/2020
Poseida Therapeutics, Inc.: Initial statement of beneficial ownership of securities
4
Thursday, 7/2/2020
Akouos, Inc.: Statement of changes in beneficial ownership of securities
3
Thursday, 6/25/2020
Akouos, Inc.: Initial statement of beneficial ownership of securities
4
Monday, 6/22/2020
Galera Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
3
Thursday, 6/18/2020
Forma Therapeutics Holdings, Inc.,: Initial statement of beneficial ownership of securities
4
Wednesday, 6/17/2020
Galera Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 6/12/2020
Galera Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 6/9/2020
Galera Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 6/4/2020
Galera Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 11/12/2019
Galera Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
3
Wednesday, 11/6/2019
Galera Therapeutics, Inc.: Initial statement of beneficial ownership of securities
4
Thursday, 5/30/2019
BICYCLE THERAPEUTICS plc: Statement of changes in beneficial ownership of securities
3
Wednesday, 5/22/2019
BICYCLE THERAPEUTICS Ltd: Initial statement of beneficial ownership of securities
4
Monday, 4/29/2019
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 4/24/2019
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 4/15/2019
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 4/10/2019
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 4/5/2019
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 4/2/2019
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Tuesday, 4/2/2019
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 3/28/2019
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 3/15/2019
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
5
Thursday, 2/14/2019
Intellia Therapeutics, Inc.: Annual statement of changes in beneficial ownership of securities
4
Thursday, 10/4/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 9/14/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 8/22/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Wednesday, 8/22/2018
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 8/20/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Thursday, 8/16/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Tuesday, 8/14/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Friday, 8/10/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Wednesday, 8/8/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Monday, 8/6/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Thursday, 8/2/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Tuesday, 7/31/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Friday, 7/27/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Wednesday, 7/25/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Wednesday, 7/18/2018
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
4
Friday, 7/13/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 6/19/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 6/15/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 5/17/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
3
Tuesday, 5/15/2018
AveXis, Inc.: Initial statement of beneficial ownership of securities
4
Monday, 5/14/2018
Aeglea BioTherapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 5/11/2018
Aeglea BioTherapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 5/9/2018
Aeglea BioTherapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 4/23/2018
Surface Oncology, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 4/18/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
3
Wednesday, 4/18/2018
Surface Oncology, Inc.: Initial statement of beneficial ownership of securities
4
Wednesday, 4/4/2018
Homology Medicines, Inc.: Statement of changes in beneficial ownership of securities
3
Tuesday, 3/27/2018
Homology Medicines, Inc.: Initial statement of beneficial ownership of securities
3
Friday, 3/23/2018
Intellia Therapeutics, Inc.: Initial statement of beneficial ownership of securities
4
Monday, 3/19/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 2/15/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
SC 13G
Wednesday, 2/14/2018
resTORbio, Inc.: Major Shareholders
SC 13D
Thursday, 2/1/2018
Advanced Accelerator Applications S.A.: Major Shareholders
4
Friday, 1/19/2018
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
SC 13G/A
Tuesday, 12/19/2017
ADURO BIOTECH, INC.: Major Shareholders
4
Friday, 12/15/2017
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 12/14/2017
Intellia Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
SC 13D/A
Tuesday, 11/28/2017
ARROWHEAD PHARMACEUTICALS, INC.: Major Shareholders
4
Thursday, 11/16/2017
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
SC 13G
Tuesday, 9/5/2017
XOMA Corp: Major Shareholders
4
Wednesday, 8/23/2017
Altimmune, Inc.: Statement of changes in beneficial ownership of securities
4
Wednesday, 7/5/2017
AILERON THERAPEUTICS INC: Statement of changes in beneficial ownership of securities
3
Wednesday, 6/28/2017
AILERON THERAPEUTICS INC: Initial statement of beneficial ownership of securities
4
Tuesday, 6/20/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 6/12/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 6/8/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 6/6/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Friday, 6/2/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 5/30/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 5/25/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 5/22/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Thursday, 5/18/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
3
Monday, 5/8/2017
Altimmune, Inc.: Initial statement of beneficial ownership of securities
4
Tuesday, 5/2/2017
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
3
Friday, 3/17/2017
Aerpio Pharmaceuticals, Inc.: Initial statement of beneficial ownership of securities
4
Friday, 3/17/2017
Aerpio Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
4
Tuesday, 3/7/2017
Intellia Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
4
Monday, 10/31/2016
Ra Pharmaceuticals, Inc.: Statement of changes in beneficial ownership of securities
3
Tuesday, 10/25/2016
Ra Pharmaceuticals, Inc.: Initial statement of beneficial ownership of securities
SC 13D/A
Tuesday, 8/30/2016
MOMENTA PHARMACEUTICALS INC: Major Shareholders
SC 13D/A
Wednesday, 8/10/2016
MOMENTA PHARMACEUTICALS INC: Major Shareholders
4
Wednesday, 5/11/2016
Intellia Therapeutics, Inc.: Statement of changes in beneficial ownership of securities
3
Thursday, 5/5/2016
Intellia Therapeutics, Inc.: Initial statement of beneficial ownership of securities
4
Tuesday, 4/12/2016
Aeglea BioTherapeutics, Inc.: Statement of changes in beneficial ownership of securities
3/A
Friday, 4/8/2016
Aeglea BioTherapeutics, Inc.: Initial statement of beneficial ownership of securities
3
Wednesday, 4/6/2016
Aeglea BioTherapeutics, Inc.: Initial statement of beneficial ownership of securities
4
Wednesday, 2/17/2016
PROTEOSTASIS THERAPEUTICS, INC.: Statement of changes in beneficial ownership of securities
SC 13D
Friday, 2/12/2016
ARROWHEAD RESEARCH CORP: Major Shareholders
3
Wednesday, 2/10/2016
PROTEOSTASIS THERAPEUTICS, INC.: Initial statement of beneficial ownership of securities
SC 13D/A
Tuesday, 12/8/2015
MOMENTA PHARMACEUTICALS INC: Major Shareholders
Prospectus (76)
S-8 POS
Thursday, 2/15/2024
Post-effective amendment to a S-8 registration statement
SC TO-C
Tuesday, 2/6/2024
Written communication relating to an issuer or third party tender offer
SC TO-C
Monday, 2/5/2024
Written communication relating to an issuer or third party tender offer
S-8 POS
Friday, 3/24/2023
Post-effective amendment to a S-8 registration statement
S-8 POS
Tuesday, 1/10/2023
Post-effective amendment to a S-8 registration statement
S-8
Thursday, 7/22/2021
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
S-8
Thursday, 11/19/2020
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
S-8 POS
Thursday, 4/30/2020
Post-effective amendment to a S-8 registration statement
S-8 POS
Thursday, 4/30/2020
Post-effective amendment to a S-8 registration statement
S-8 POS
Thursday, 4/30/2020
Post-effective amendment to a S-8 registration statement
S-8 POS
Thursday, 4/30/2020
Post-effective amendment to a S-8 registration statement
FWP
Wednesday, 2/12/2020
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B5
Wednesday, 2/12/2020
Prospectus filed pursuant to Rule 424(b)(5)
424B5
Tuesday, 2/11/2020
Prospectus filed pursuant to Rule 424(b)(5)
SC TO-T/A
Monday, 1/6/2020
Third party tender offer statement
SC TO-T/A
Monday, 12/23/2019
Third party tender offer statement
SC TO-T/A
Thursday, 12/19/2019
Third party tender offer statement
SC TO-T
Thursday, 12/5/2019
Third party tender offer statement
SC TO-C
Monday, 11/25/2019
Written communication relating to an issuer or third party tender offer
SC TO-C
Monday, 11/25/2019
Written communication relating to an issuer or third party tender offer
SC TO-T/A
Tuesday, 5/15/2018
Third party tender offer statement
SC TO-T/A
Tuesday, 5/1/2018
Third party tender offer statement
SC TO-T
Tuesday, 4/17/2018
Third party tender offer statement
SC TO-C
Tuesday, 4/10/2018
Written communication relating to an issuer or third party tender offer
SC TO-C
Monday, 4/9/2018
Written communication relating to an issuer or third party tender offer
SC TO-T/A
Thursday, 2/1/2018
Third party tender offer statement
SC TO-T/A
Monday, 1/22/2018
Third party tender offer statement
SC TO-T/A
Friday, 1/12/2018
Third party tender offer statement
SC TO-T/A
Thursday, 12/21/2017
Third party tender offer statement
SC TO-T
Thursday, 12/7/2017
Third party tender offer statement
SC TO-C
Friday, 11/24/2017
Written communication relating to an issuer or third party tender offer
SC TO-C
Monday, 10/30/2017
Written communication relating to an issuer or third party tender offer
S-8 POS
Wednesday, 3/15/2017
Post-effective amendment to a S-8 registration statement
424B5
Wednesday, 2/15/2017
Prospectus filed pursuant to Rule 424(b)(5)
FWP
Tuesday, 2/14/2017
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B5
Tuesday, 2/14/2017
Prospectus filed pursuant to Rule 424(b)(5)
424B5
Wednesday, 11/18/2015
Prospectus filed pursuant to Rule 424(b)(5)
FWP
Wednesday, 11/18/2015
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B5
Tuesday, 11/17/2015
Prospectus filed pursuant to Rule 424(b)(5)
S-8
Friday, 9/12/2014
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
424B5
Wednesday, 2/19/2014
Prospectus filed pursuant to Rule 424(b)(5)
424B5
Tuesday, 2/18/2014
Prospectus filed pursuant to Rule 424(b)(5)
FWP
Tuesday, 2/18/2014
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B5
Wednesday, 9/19/2012
Prospectus filed pursuant to Rule 424(b)(5)
FWP
Wednesday, 9/19/2012
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B5
Tuesday, 9/18/2012
Prospectus filed pursuant to Rule 424(b)(5)
S-8
Friday, 4/8/2011
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
SC TO-T/A
Monday, 3/7/2011
Third party tender offer statement
424B3
Monday, 2/28/2011
Prospectus filed pursuant to Rule 424(b)(3)
SC TO-T/A
Monday, 2/28/2011
Third party tender offer statement
SC TO-T/A
Tuesday, 2/22/2011
Third party tender offer statement
SC TO-T/A
Monday, 2/7/2011
Third party tender offer statement
SC TO-T
Friday, 1/28/2011
Third party tender offer statement
SC TO-C
Wednesday, 1/26/2011
Written communication relating to an issuer or third party tender offer
SC TO-C
Monday, 1/24/2011
Written communication relating to an issuer or third party tender offer
SC TO-C
Monday, 1/24/2011
Written communication relating to an issuer or third party tender offer
S-8
Tuesday, 1/18/2011
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
425
Wednesday, 12/15/2010
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425
Wednesday, 12/15/2010
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
424B5
Wednesday, 3/10/2010
Prospectus filed pursuant to Rule 424(b)(5)
FWP
Wednesday, 3/10/2010
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B5
Tuesday, 3/9/2010
Prospectus filed pursuant to Rule 424(b)(5)
425
Monday, 1/4/2010
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425
Monday, 1/4/2010
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425
Monday, 1/4/2010
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425
Monday, 1/4/2010
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425
Monday, 1/4/2010
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
S-8
Thursday, 10/29/2009
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
424B2
Friday, 2/6/2009
Prospectus filed pursuant to Rule 424(b)(2)
FWP
Wednesday, 2/4/2009
Filing under Securities Act Rules 163/433 of free writing prospectuses
424B5
Tuesday, 2/3/2009
Prospectus filed pursuant to Rule 424(b)(5)
424B3
Tuesday, 2/27/2007
Prospectus filed pursuant to Rule 424(b)(3)
S-8
Tuesday, 9/5/2006
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
SC TO-C
Tuesday, 2/22/2005
Written communication relating to an issuer or third party tender offer
S-8
Friday, 10/1/2004
Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
424B3
Wednesday, 7/21/2004
Prospectus filed pursuant to Rule 424(b)(3)
Proxies (8)
DFAN14A
Monday, 7/10/2023
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
DFAN14A
Monday, 6/12/2023
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
DFAN14A
Tuesday, 11/6/2018
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
DFAN14A
Monday, 11/5/2018
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
DFAN14A
Thursday, 10/18/2018
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
DFAN14A
Thursday, 10/18/2018
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
DFAN14A
Thursday, 10/18/2018
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
DFAN14A
Thursday, 10/18/2018
Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material